Literature DB >> 9240343

Discovery of potent nonpeptide vitronectin receptor (alpha v beta 3) antagonists.

R M Keenan1, W H Miller, C Kwon, F E Ali, J F Callahan, R R Calvo, S M Hwang, K D Kopple, C E Peishoff, J M Samanen, A S Wong, C K Yuan, W F Huffman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9240343     DOI： 10.1021/jm970205r

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  7 in total

1.  Cell contact-dependent activation of alpha3beta1 integrin modulates endothelial cell responses to thrombospondin-1.

Authors:  L Chandrasekaran; C Z He; H Al-Barazi; H C Krutzsch; M L Iruela-Arispe; D D Roberts
Journal:  Mol Biol Cell       Date:  2000-09       Impact factor: 4.138

Review 2.  The significance of G protein-coupled receptor crystallography for drug discovery.

Authors:  John A Salon; David T Lodowski; Krzysztof Palczewski
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

3.  Shear stress induced release of von Willebrand factor and thrombospondin-1 in HUVEC extracellular matrix enhances breast tumour cell adhesion.

Authors:  Noëlia Gomes; Chantal Legrand; Françoise Fauvel-Lafève
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

4.  Synthesis of Tetrazolo-Fused Benzodiazepines and Benzodiazepinones by a Two-Step Protocol Using an Ugi-Azide Reaction for Initial Diversity Generation.

Authors:  Steven Gunawan; Muhammad Ayaz; Fabio De Moliner; Brendan Frett; Christine Kaiser; Nina Patrick; Zhigang Xu; Christopher Hulme
Journal:  Tetrahedron       Date:  2012-04-26       Impact factor: 2.457

5.  The integrin alphavbeta3 is a receptor for the latency-associated peptides of transforming growth factors beta1 and beta3.

Authors:  Steven B Ludbrook; Simon T Barry; Chris J Delves; Carmel M T Horgan
Journal:  Biochem J       Date:  2003-01-15       Impact factor: 3.857

Review 6.  Emerging molecular diversity from the intra-molecular Ugi reaction: iterative efficiency in medicinal chemistry.

Authors:  Christopher Hulme; Justin Dietrich
Journal:  Mol Divers       Date:  2009-02-11       Impact factor: 3.364

Review 7.  Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation.

Authors:  Carlos Mas-Moruno; Florian Rechenmacher; Horst Kessler
Journal:  Anticancer Agents Med Chem       Date:  2010-12       Impact factor: 2.505
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.